American Health & Drug Benefits

Recent Articles

Multiple Myeloma

Novel BCMA-Directed CAR T-Cell Therapy Had Excellent Responses in Heavily Pretreated Patients with Multiple Myeloma

Phoebe Starr

Emerging Therapies

Mosunetuzumab, a Dual-Targeted Antibody, Shows Complete Remissions in Relapsed/Refractory NHL After CAR T-Cell Therapy

Phoebe Starr

Leukemia, Value-Based Care

First National Study: Geographic Socioeconomic Disparities Mirror Substantial Gaps in Survival in Children with AML

Chase Doyle

Business, Original Research

Association Between Formulary Coverage and Use of Abuse-Deterrent Prescription Opioids, Risk for Abuse or Overdose, and Associated Healthcare Resource Utilization

Allison Petrilla, MPH, Elizabeth Marrett, MPH, Xian Shen, PhD, MS, BS, Winghan Jacqueline Kwong, PharmD, PhD, Edmund Pezalla, MD, MPH

Stakeholder Perspective

Abuse-Deterrent Formulations of Prescription Opioids: A Missed Opportunity to Address the Current Opioid Crisis?

by Atheer A. Kaddis, PharmD

Conference Highlights ASH

Advances in Cellular Therapies for Hematologic Malignancies Highlighted at ASH 2019

Wayne Kuznar

Clinical, Original Research

Medication Use Before and After Hospitalization for Chronic Obstructive Pulmonary Disease in a Cohort of Elderly Patients with a Medicare Advantage Plan

Qingqing Xu, MS, Sarah S. Laxa, PharmD, Omar Serna, PharmD, BCACP, Sujit S. Sansgiry, MS, PhD

Stakeholder Perspective

Improving Medication Use for Chronic Diseases by Reducing Costs, Increasing Patient Adherence

by F. Randy Vogenberg, PhD, FASHP

Corporate Culture of Health: Elusive and Expensive

David B. Nash, MD, MBA

Paying Tribute to Geno J. Merli, MD, MACP

David B. Nash, MD, MBA

The Business Case for Social Determinants

David B. Nash, MD, MBA

Most Popular Articles

Clinical, Review Article

The Challenge of Managing Atopic Dermatitis in the United States

Steven R. Feldman, MD, PhD, Linda S. Cox, MD, Lindsay C. Strowd, MD, Robert A. Gerber, PharmD, MA, MBA, Steven Faulkner, PharmD, MBA, Debra Sierka, PharmD, Timothy W. Smith, BA, Joseph C. Cappelleri, PhD, Mark E. Levenberg, DO

Select Drug Profiles

Balversa (Erdafitinib), First-in-Class FGFR Kinase Inhibitor, Approved for Patients with Metastatic Urothelial Carcinoma and FGFR Mutations

Loretta Fala

Editorial

The Business Case for Social Determinants

David B. Nash, MD, MBA

Clinical, Original Research

Charlson Comorbidity Index: ICD-9 Update and ICD-10 Translation

William P. Glasheen, PhD, Tristan Cordier, MPH, Rajiv Gumpina, MS, Gilbert S. Haugh, MS, Jared Davis, MD, MBA, Andrew Renda, MD, MPH

Select Drug Profiles

Lutathera (Lutetium Lu 177 Dotatate) First Radioactive Drug Approved for Gastroenteropancreatic Neuroendocrine Tumors

Lisa A. Raedler, PhD, RPh

Business, Original Research

Association Between Formulary Coverage and Use of Abuse-Deterrent Prescription Opioids, Risk for Abuse or Overdose, and Associated Healthcare Resource Utilization

Allison Petrilla, MPH, Elizabeth Marrett, MPH, Xian Shen, PhD, MS, BS, Winghan Jacqueline Kwong, PharmD, PhD, Edmund Pezalla, MD, MPH

Web Exclusives

Health Policy and Reform, In the News

CMS Expands Access to Telehealth Benefits During COVID-19 Outbreak

FDA Approvals

Sarclisa Newest Treatment Approved by the FDA for Patients with Multiple Myeloma

In the Literature

Luspatercept Effective in Patients with Lower-Risk Myelodysplastic Syndromes